about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Roche schiz­o­phre­nia drug that failed PhI­II gets a new life in rare dis­or­der as Or­biMed leads $90M for start­up

4 years ago
Financing
Startups

FDA posed a sprawl­ing set of ques­tions for two-day gene ther­a­py hear­ing. Here's what com­pa­nies and ex­perts will be ...

4 years ago
Cell/Gene Tx
FDA+

Te­va re­cruits Tal Zaks to its board, of­fer­ing $300K+ pay pack­age and seam­less tran­si­tion from Mod­er­na

4 years ago
People

Flag­ship woos an­oth­er Big Phar­ma BD ex­ec to biotech. Red blood cell ther­a­pies any­one?

4 years ago
People

Sanofi, Re­gen­eron bur­nish their block­buster Dupix­ent fran­chise with pos­i­tive re­sults in chil­dren with un­con­trolled ...

4 years ago
R&D
Pharma

The past and fu­ture of an­ti­bod­ies, as told through HIV; An­oth­er big phar­ma joins CD47 game; and more

4 years ago
Weekly

On the back of PhI­II suc­cess, As­traZeneca lays out the red car­pet for rare dis­ease drug Alex­ion paid $855M for

4 years ago
R&D

Alzheimer's biotech comes un­der at­tack as pe­ti­tion calls for tri­al halt, da­ta au­dit — and it's fight­ing back

4 years ago
R&D

An­oth­er Covid-19 an­ti­body cock­tail on the menu? Brii Bio touts ear­ly win in NIH study for a com­bo al­ready used in ...

4 years ago
R&D
Coronavirus

Im­muno­core's bis­pe­cif­ic lands speedy re­view with FDA, EMA; Low-pro­file gene ther­a­py play­er grabs $30M

4 years ago
News Briefing

No­var­tis' CAR-T fails to help a vul­ner­a­ble group of NHL pa­tients — quash­ing hope of mov­ing up lines of treat­ment

4 years ago
R&D
Cell/Gene Tx

Cap­ping AAV dose? Tweak­ing gene ther­a­py tri­als? New an­i­mal mod­els? FDA pos­es far-reach­ing ques­tions for ex­perts

4 years ago
Cell/Gene Tx
FDA+

Vac­cine man­dates, bio­phar­ma edi­tion; Alzheimer’s rip­ple ef­fect; Change of guard at J&J; and more

4 years ago
Weekly

While fig­ur­ing out post-CRL fu­ture for rox­adu­s­tat, Fi­bro­Gen cel­e­brates Eu­rope OK with Astel­las

4 years ago
FDA+

As­traZeneca cuts PhI­II ALS study af­ter Alex­ion's Ul­tomiris shows 'lack of ef­fi­ca­cy'

4 years ago
R&D

Jun­shi, Co­herus gun for ma­jor PD-(L)1 mar­ket with PhI­II NSCLC re­sults

4 years ago
China

Ver­i­ly scoops up a fel­low soft­ware mak­er as Amy Aber­nethy scales its clin­i­cal tri­als plat­form

4 years ago
Deals
Outsourcing

Tout­ing CD161 as a test case for sin­gle-cell tech, Long­wood-backed Im­mu­ni­tas bags $58M for next-gen I/O work

4 years ago
Financing

Search­ing for ways to boost CAR-T re­sponse, Penn re­searchers find a ca­pa­ble wing­man in BET in­hibitors

4 years ago
Discovery
Cell/Gene Tx

End­points News wants to know: Is your com­pa­ny man­dat­ing Covid-19 vac­cines?

4 years ago
Editor's note
Pharma

Can­cer spe­cial­ist Hi­ber­Cell snaps up an­a­lyt­ics, com­pu­ta­tion­al tools in all-stock buy­out; Prax­is re­veals new ...

4 years ago
News Briefing

Af­ter at­tract­ing mul­ti­ple Chi­nese phar­ma part­ners, XtalPi grabs an­oth­er $400M to re­fine AI for drug dis­cov­ery

4 years ago
Financing
China

As US re­view of Eli Lil­ly-part­nered PD-1 gets un­der­way, In­novent touts an­oth­er front­line win in Chi­na

4 years ago
R&D
China

Lat­est news on Fri­day af­ter­noon CRL; A big no to Aduhelm; Re­mem­ber­ing Tachi with Jim Wil­son and Bill Clin­ton; and ...

4 years ago
Weekly
First page Previous page 45464748495051 Next page Last page
A service from the Financial Times